Global Pergoveris Market 2026 advancing reproductive medicine

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Pergoveris Market By 2030 Starting From Its 2026 Size?

Historical growth stemmed from more frequent identification of gonadotropin deficiencies, the proliferation of assisted reproductive technology clinics, improved success rates for IVF treatments, the presence of recombinant hormone technologies, and enhanced awareness regarding infertility.

The anticipated expansion during the forecast period is propelled by the escalating requirement for sophisticated IVF protocols, a heightened emphasis on individualized hormone therapy, the broadening reach of fertility tourism, the increasing uptake of user-friendly injectable formats, and a surge in investments within reproductive biotechnology.

Prominent trends anticipated over the projection period include a wider embrace of recombinant hormone treatments, a growing need for IVF and Assisted Reproductive Technology (ART) interventions, the increasing application of pen-based injectable formulations, the broadening scope of precisely regulated fertility therapies, and a magnified focus on addressing hormone insufficiencies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20181&type=smp

What Drivers Are Shaping The Future Growth Of The Pergoveris Market?

The pergoveris market is anticipated to see growth moving forward, driven by the increasing prevalence of infertility. Infertility describes the inability to become pregnant, sustain a pregnancy, or carry it to term. Its rise is attributed to factors such as delayed childbearing, lifestyle choices, environmental toxins, and the growing incidence of medical conditions like polycystic ovary syndrome (PCOS) and endometriosis. Pergoveris aids infertility patients by stimulating ovarian function through a blend of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby promoting egg development in women with severe gonadotropin deficiency. For instance, in April 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 17.5% of the global adult population, or about 1 in 6 individuals, experience infertility. Consequently, the rising prevalence of infertility is propelling the expansion of the pergoveris market.

Pergoveris Market Driver: Increasing Adoption Of IVF Procedures Driving Growth In The Market

Which Segment Categories Define The Pergoveris Market?

The pergoveris market covered in this report is segmented –

1) By Formulation: Injectable Pen, Vial Formulation

2) By Indication: Anovulation, Assisted Reproductive Technology (ART) Procedures

3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Major Market Trends Are Driving Changes In The Pergoveris Market?

Leading companies in the pergoveris market are concentrating on regulatory and access improvements, including priority-review filings through the FDA Commissioner’s National Priority Voucher (CNPV) program, aiming to shorten approval times, broaden patient access, and enhance the affordability of intricate fertility treatments. This type of filing enables regulatory bodies to reduce the typical 10–12 month review period down to 1–2 months, thereby accelerating the introduction of novel reproductive therapies without compromising safety or effectiveness. As an example, EMD Serono, the healthcare division of Merck KGaA, Darmstadt, Germany, submitted Pergoveris® for approval under the FDA CNPV program in October 2025. The therapy itself integrates recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) at a 2:1 ratio, administered through a pre-filled Redi-ject® pen designed to streamline dosing, decrease the number of injections, and improve overall patient convenience. Pergoveris is formulated to replicate natural reproductive physiology, facilitating follicular development and maturation during medically assisted reproductive cycles. Furthermore, the program is consistent with public-private collaborations and direct-to-consumer access efforts, leading to improved affordability and a wider range of treatment choices for women experiencing severe FSH/LH deficiency.

Who Are The Top Companies Competing In The Pergoveris Market?

Major companies operating in the pergoveris market are Merck KGaA

Read the full pergoveris market report here:

https://www.thebusinessresearchcompany.com/report/pergoveris-global-market-report

Which Geographic Regions Are Influencing Demand In The Pergoveris Market?

Europe was the largest region in the pergoveris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pergoveris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pergoveris Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20181&type=smp

Browse Through More Reports Similar to the Global Pergoveris Market 2026, By The Business Research Company

Peristaltic Pumps Market Report 2026

https://www.thebusinessresearchcompany.com/report/peristaltic-pumps-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795